Annual report
2784.TEDINET S100YH29
Period2025-04-01 → 2026-03-31
Filed2026-06-23
StandardJapan GAAP
ConsolidatedYes
Data checks24 of 24 passed
Key figures · 148
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥3.10T | 2025-04-01 → 2026-03-31 | Cons. | Net sales |
| Revenue | ¥2.96T | 2024-04-01 → 2025-03-31 | Cons. | Net sales |
| Revenue | ¥2.86T | 2023-04-01 → 2024-03-31v | Cons. | Net sales (5-year summary) |
| Revenue | ¥2.70T | 2022-04-01 → 2023-03-31v | Cons. | Net sales (5-year summary) |
| Revenue | ¥2.59T | 2021-04-01 → 2022-03-31v | Cons. | Net sales (5-year summary) |
| Operating income | ¥36.2bn | 2025-04-01 → 2026-03-31 | Cons. | Operating income |
| Operating income | ¥38.1bn | 2024-04-01 → 2025-03-31 | Cons. | Operating income |
| Ordinary income | ¥38.6bn | 2025-04-01 → 2026-03-31 | Cons. | Ordinary income |
| Ordinary income | ¥40.5bn | 2024-04-01 → 2025-03-31 | Cons. | Ordinary income |
| Ordinary income | ¥40.0bn | 2023-04-01 → 2024-03-31v | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥32.8bn | 2022-04-01 → 2023-03-31v | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥32.6bn | 2021-04-01 → 2022-03-31v | Cons. | Ordinary income loss (5-year summary) |
| Profit before tax | ¥62.0bn | 2025-04-01 → 2026-03-31 | Cons. | Income before income taxes |
| Profit before tax | ¥39.4bn | 2024-04-01 → 2025-03-31 | Cons. | Income before income taxes |
| Net income (owners) | ¥41.7bn | 2025-04-01 → 2026-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥27.4bn | 2024-04-01 → 2025-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥29.6bn | 2023-04-01 → 2024-03-31v | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥25.8bn | 2022-04-01 → 2023-03-31v | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥32.2bn | 2021-04-01 → 2022-03-31v | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income | ¥41.8bn | 2025-04-01 → 2026-03-31 | Cons. | Profit loss |
| Net income | ¥27.4bn | 2024-04-01 → 2025-03-31 | Cons. | Profit loss |
| Total assets | ¥1.51T | at 2026-03-31 | Cons. | Assets |
| Total assets | ¥1.44T | at 2025-03-31 | Cons. | Assets |
| Total assets | ¥1.45T | at 2024-03-31v | Cons. | Total assets (5-year summary) |
| Total assets | ¥1.34T | at 2023-03-31v | Cons. | Total assets (5-year summary) |
| Total assets | ¥1.30T | at 2022-03-31v | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥999.1bn | at 2026-03-31 | Cons. | Liabilities |
| Total liabilities | ¥957.6bn | at 2025-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥507.9bn | at 2026-03-31 | Cons. | Net assets |
| Net assets / equity | ¥482.2bn | at 2025-03-31 | Cons. | Net assets |
| Net assets / equity | ¥479.9bn | at 2024-03-31v | Cons. | Net assets |
| Net assets / equity | ¥488.3bn | at 2023-03-31v | Cons. | Net assets (5-year summary) |
| Net assets / equity | ¥471.8bn | at 2022-03-31v | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥193.1bn | at 2026-03-31 | Cons. | Cash and deposits |
| Cash and deposits | ¥177.1bn | at 2025-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥190.7bn | at 2026-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥174.8bn | at 2025-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥212.3bn | at 2024-03-31v | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥158.8bn | at 2023-03-31v | Cons. | Cash and cash equivalents (5-year summary) |
| Cash & equivalents | ¥179.1bn | at 2022-03-31v | Cons. | Cash and cash equivalents (5-year summary) |
| Operating cash flow | ¥38.6bn | 2025-04-01 → 2026-03-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥5.6bn | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥86.4bn | 2023-04-01 → 2024-03-31v | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥13.1bn | 2022-04-01 → 2023-03-31v | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥36.5bn | 2021-04-01 → 2022-03-31v | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Investing cash flow | −¥8.7bn | 2025-04-01 → 2026-03-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥24.9bn | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥14.2bn | 2023-04-01 → 2024-03-31v | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥20.5bn | 2022-04-01 → 2023-03-31v | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | ¥2.3bn | 2021-04-01 → 2022-03-31v | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Financing cash flow | −¥14.0bn | 2025-04-01 → 2026-03-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥23.5bn | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥19.7bn | 2023-04-01 → 2024-03-31v | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥12.9bn | 2022-04-01 → 2023-03-31v | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥29.2bn | 2021-04-01 → 2022-03-31v | Cons. | Net cash provided by used in financing activities (5-year summary) |
| EPS (basic) | ¥229.64 | 2025-04-01 → 2026-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥147.54 | 2024-04-01 → 2025-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥154.13 | 2023-04-01 → 2024-03-31v | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥127.42 | 2022-04-01 → 2023-03-31v | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥153.57 | 2021-04-01 → 2022-03-31v | Cons. | Basic earnings loss per share (5-year summary) |
| Net assets per share | ¥2,792.01 | at 2026-03-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥2,650.27 | at 2025-03-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥2,566.5 | at 2024-03-31v | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥2,411.89 | at 2023-03-31v | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥2,330.36 | at 2022-03-31v | Cons. | Net assets per share (5-year summary) |
| Equity ratio | 33.7% | at 2026-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 33.5% | at 2025-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 33.1% | at 2024-03-31v | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 36.4% | at 2023-03-31v | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 36.2% | at 2022-03-31v | Cons. | Equity to asset ratio (5-year summary) |
| ROE | 8.4% | 2025-04-01 → 2026-03-31 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 5.7% | 2024-04-01 → 2025-03-31 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 6.1% | 2023-04-01 → 2024-03-31v | Cons. | Rate of return on equity (5-year summary) |
| ROE | 5.4% | 2022-04-01 → 2023-03-31v | Cons. | Rate of return on equity (5-year summary) |
| ROE | 6.7% | 2021-04-01 → 2022-03-31v | Cons. | Rate of return on equity (5-year summary) |
| Employees | 12,525 | at 2026-03-31 | Cons. | Number of employees |
| Employees | 12,452 | at 2025-03-31 | Cons. | Number of employees |
| Employees | 12,517 | at 2024-03-31v | Cons. | Number of employees |
| Employees | 11,772 | at 2023-03-31v | Cons. | Number of employees |
| Employees | 11,925 | at 2022-03-31v | Cons. | Number of employees |
| Revenue | ¥19.5bn | 2025-04-01 → 2026-03-31 | Standalone | Operating revenue1 |
| Revenue | ¥20.5bn | 2024-04-01 → 2025-03-31 | Standalone | Operating revenue1 |
| Revenue | ¥17.3bn | 2023-04-01 → 2024-03-31v | Standalone | Operating revenue1 (5-year summary) |
| Revenue | ¥22.2bn | 2022-04-01 → 2023-03-31v | Standalone | Operating revenue1 (5-year summary) |
| Revenue | ¥17.2bn | 2021-04-01 → 2022-03-31v | Standalone | Operating revenue1 (5-year summary) |
| Operating income | ¥15.9bn | 2025-04-01 → 2026-03-31 | Standalone | Operating income |
| Operating income | ¥18.0bn | 2024-04-01 → 2025-03-31 | Standalone | Operating income |
| Ordinary income | ¥15.8bn | 2025-04-01 → 2026-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥18.0bn | 2024-04-01 → 2025-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥14.2bn | 2023-04-01 → 2024-03-31v | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥20.3bn | 2022-04-01 → 2023-03-31v | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥15.4bn | 2021-04-01 → 2022-03-31v | Standalone | Ordinary income loss (5-year summary) |
| Profit before tax | ¥17.9bn | 2025-04-01 → 2026-03-31 | Standalone | Income before income taxes |
| Profit before tax | ¥18.1bn | 2024-04-01 → 2025-03-31 | Standalone | Income before income taxes |
| Net income | ¥16.8bn | 2025-04-01 → 2026-03-31 | Standalone | Profit loss |
| Net income | ¥18.4bn | 2024-04-01 → 2025-03-31 | Standalone | Profit loss |
| Net income | ¥13.3bn | 2023-04-01 → 2024-03-31v | Standalone | Net income loss (5-year summary) |
| Net income | ¥20.4bn | 2022-04-01 → 2023-03-31v | Standalone | Net income loss (5-year summary) |
| Net income | ¥13.6bn | 2021-04-01 → 2022-03-31v | Standalone | Net income loss (5-year summary) |
| Total assets | ¥275.6bn | at 2026-03-31 | Standalone | Assets |
| Total assets | ¥272.8bn | at 2025-03-31 | Standalone | Assets |
| Total assets | ¥266.9bn | at 2024-03-31v | Standalone | Total assets (5-year summary) |
| Total assets | ¥271.9bn | at 2023-03-31v | Standalone | Total assets (5-year summary) |
| Total assets | ¥265.3bn | at 2022-03-31v | Standalone | Total assets (5-year summary) |
| Total liabilities | ¥55.3bn | at 2026-03-31 | Standalone | Liabilities |
| Total liabilities | ¥53.8bn | at 2025-03-31 | Standalone | Liabilities |
| Net assets / equity | ¥220.4bn | at 2026-03-31 | Standalone | Net assets |
| Net assets / equity | ¥219.0bn | at 2025-03-31 | Standalone | Net assets |
| Net assets / equity | ¥223.4bn | at 2024-03-31v | Standalone | Net assets |
| Net assets / equity | ¥256.8bn | at 2023-03-31v | Standalone | Net assets (5-year summary) |
| Net assets / equity | ¥247.6bn | at 2022-03-31v | Standalone | Net assets (5-year summary) |
| Cash and deposits | ¥5.5bn | at 2026-03-31 | Standalone | Cash and deposits |
| Cash and deposits | ¥13.4bn | at 2025-03-31 | Standalone | Cash and deposits |
| EPS (basic) | ¥92.26 | 2025-04-01 → 2026-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥98.99 | 2024-04-01 → 2025-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥69.32 | 2023-04-01 → 2024-03-31v | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥100.79 | 2022-04-01 → 2023-03-31v | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥64.88 | 2021-04-01 → 2022-03-31v | Standalone | Basic earnings loss per share (5-year summary) |
| Dividend per share | ¥68 | 2025-04-01 → 2026-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥63 | 2024-04-01 → 2025-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥70 | 2023-04-01 → 2024-03-31v | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥57 | 2022-04-01 → 2023-03-31v | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥54 | 2021-04-01 → 2022-03-31v | Standalone | Dividend paid per share (5-year summary) |
| Net assets per share | ¥1,212.69 | at 2026-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥1,204.83 | at 2025-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥1,195.52 | at 2024-03-31v | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥1,269.01 | at 2023-03-31v | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥1,223.58 | at 2022-03-31v | Standalone | Net assets per share (5-year summary) |
| Equity ratio | 79.9% | at 2026-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 80.3% | at 2025-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 83.7% | at 2024-03-31v | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 94.4% | at 2023-03-31v | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 93.3% | at 2022-03-31v | Standalone | Equity to asset ratio (5-year summary) |
| ROE | 7.6% | 2025-04-01 → 2026-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 8.3% | 2024-04-01 → 2025-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 5.5% | 2023-04-01 → 2024-03-31v | Standalone | Rate of return on equity (5-year summary) |
| ROE | 8.1% | 2022-04-01 → 2023-03-31v | Standalone | Rate of return on equity (5-year summary) |
| ROE | 5.3% | 2021-04-01 → 2022-03-31v | Standalone | Rate of return on equity (5-year summary) |
| Shares issued | 191,300,000 | at 2026-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 191,300,000 | at 2025-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 202,840,000 | at 2024-03-31v | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 202,840,000 | at 2023-03-31v | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 235,017,000 | at 2022-03-31v | Standalone | Total number of issued shares (5-year summary) |
| Employees | 67 | at 2026-03-31 | Standalone | Number of employees |
| Employees | 56 | at 2025-03-31 | Standalone | Number of employees |
| Employees | 51 | at 2024-03-31v | Standalone | Number of employees |
| Employees | 47 | at 2023-03-31v | Standalone | Number of employees |
| Employees | 44 | at 2022-03-31v | Standalone | Number of employees |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 89
| Segment | Item | Period | Value |
|---|---|---|---|
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | employees | at 2026-03-31 | 45 pure |
| Otherother segments | capex | 2025-04-01 → 2026-03-31 | ¥55m |
| Otherother segments | depreciation | 2025-04-01 → 2026-03-31 | ¥104m |
| Otherother segments | segment assets | at 2026-03-31 | ¥2.0bn |
| Otherother segments | segment profit | 2025-04-01 → 2026-03-31 | −¥1.1bn |
| Reconciling Itemsreconciling | capex | 2025-04-01 → 2026-03-31 | ¥7.4bn |
| Reconciling Itemsreconciling | depreciation | 2025-04-01 → 2026-03-31 | ¥2.8bn |
| Reconciling Itemsreconciling | revenue | 2025-04-01 → 2026-03-31 | −¥34.9bn |
| Reconciling Itemsreconciling | revenue intersegment | 2025-04-01 → 2026-03-31 | −¥34.9bn |
| Reconciling Itemsreconciling | segment assets | at 2026-03-31 | ¥4.8bn |
| Reconciling Itemsreconciling | segment profit | 2025-04-01 → 2026-03-31 | −¥749m |
| Dispensing Pharmacy And Related Businessesreportable segment | capex | 2025-04-01 → 2026-03-31 | ¥405m |
| Dispensing Pharmacy And Related Businessesreportable segment | depreciation | 2025-04-01 → 2026-03-31 | ¥434m |
| Dispensing Pharmacy And Related Businessesreportable segment | employees | at 2026-03-31 | 1112 pure |
| Dispensing Pharmacy And Related Businessesreportable segment | revenue | 2025-04-01 → 2026-03-31 | ¥37.2bn |
| Dispensing Pharmacy And Related Businessesreportable segment | revenue external | 2025-04-01 → 2026-03-31 | ¥37.2bn |
| Dispensing Pharmacy And Related Businessesreportable segment | segment assets | at 2026-03-31 | ¥17.0bn |
| Dispensing Pharmacy And Related Businessesreportable segment | segment profit | 2025-04-01 → 2026-03-31 | ¥499m |
| Ethical Pharmaceuticals Wholesaling Businessreportable segment | capex | 2025-04-01 → 2026-03-31 | ¥12.6bn |
| Ethical Pharmaceuticals Wholesaling Businessreportable segment | depreciation | 2025-04-01 → 2026-03-31 | ¥7.7bn |
| Ethical Pharmaceuticals Wholesaling Businessreportable segment | employees | at 2026-03-31 | 9427 pure |
| Ethical Pharmaceuticals Wholesaling Businessreportable segment | revenue | 2025-04-01 → 2026-03-31 | ¥2.78T |
| Ethical Pharmaceuticals Wholesaling Businessreportable segment | revenue external | 2025-04-01 → 2026-03-31 | ¥2.76T |
| Ethical Pharmaceuticals Wholesaling Businessreportable segment | revenue intersegment | 2025-04-01 → 2026-03-31 | ¥19.5bn |
| Ethical Pharmaceuticals Wholesaling Businessreportable segment | segment assets | at 2026-03-31 | ¥1.31T |
| Ethical Pharmaceuticals Wholesaling Businessreportable segment | segment profit | 2025-04-01 → 2026-03-31 | ¥33.3bn |
| Manufacturing Businessreportable segment | capex | 2025-04-01 → 2026-03-31 | ¥20.3bn |
| Manufacturing Businessreportable segment | depreciation | 2025-04-01 → 2026-03-31 | ¥3.2bn |
| Manufacturing Businessreportable segment | employees | at 2026-03-31 | 1383 pure |
| Manufacturing Businessreportable segment | revenue | 2025-04-01 → 2026-03-31 | ¥52.2bn |
| Manufacturing Businessreportable segment | revenue external | 2025-04-01 → 2026-03-31 | ¥37.2bn |
| Manufacturing Businessreportable segment | revenue intersegment | 2025-04-01 → 2026-03-31 | ¥15.0bn |
| Manufacturing Businessreportable segment | segment assets | at 2026-03-31 | ¥80.1bn |
| Manufacturing Businessreportable segment | segment profit | 2025-04-01 → 2026-03-31 | ¥1.2bn |
| Self Medication Products Wholesaling Businessreportable segment | capex | 2025-04-01 → 2026-03-31 | ¥233m |
| Self Medication Products Wholesaling Businessreportable segment | depreciation | 2025-04-01 → 2026-03-31 | ¥384m |
| Self Medication Products Wholesaling Businessreportable segment | employees | at 2026-03-31 | 392 pure |
| Self Medication Products Wholesaling Businessreportable segment | revenue | 2025-04-01 → 2026-03-31 | ¥267.1bn |
| Self Medication Products Wholesaling Businessreportable segment | revenue external | 2025-04-01 → 2026-03-31 | ¥266.6bn |
| Self Medication Products Wholesaling Businessreportable segment | revenue intersegment | 2025-04-01 → 2026-03-31 | ¥447m |
| Self Medication Products Wholesaling Businessreportable segment | segment assets | at 2026-03-31 | ¥91.9bn |
| Self Medication Products Wholesaling Businessreportable segment | segment profit | 2025-04-01 → 2026-03-31 | ¥3.0bn |
| Total Of Reportable Segments And Otherssegment total | capex | 2025-04-01 → 2026-03-31 | ¥33.5bn |
| Total Of Reportable Segments And Otherssegment total | depreciation | 2025-04-01 → 2026-03-31 | ¥11.7bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2025-04-01 → 2026-03-31 | ¥3.14T |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2025-04-01 → 2026-03-31 | ¥3.10T |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2025-04-01 → 2026-03-31 | ¥34.9bn |
| Total Of Reportable Segments And Otherssegment total | segment assets | at 2026-03-31 | ¥1.50T |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2025-04-01 → 2026-03-31 | ¥38.0bn |
| Reconciling Itemsreconciling | capex | 2024-04-01 → 2025-03-31 | ¥2.6bn |
| Reconciling Itemsreconciling | depreciation | 2024-04-01 → 2025-03-31 | ¥2.5bn |
| Reconciling Itemsreconciling | revenue | 2024-04-01 → 2025-03-31 | −¥35.8bn |
| Reconciling Itemsreconciling | revenue intersegment | 2024-04-01 → 2025-03-31 | −¥35.8bn |
| Reconciling Itemsreconciling | segment assets | at 2025-03-31 | ¥19.3bn |
| Reconciling Itemsreconciling | segment profit | 2024-04-01 → 2025-03-31 | ¥183m |
| Dispensing Pharmacy And Related Businessesreportable segment | capex | 2024-04-01 → 2025-03-31 | ¥741m |
| Dispensing Pharmacy And Related Businessesreportable segment | depreciation | 2024-04-01 → 2025-03-31 | ¥376m |
| Dispensing Pharmacy And Related Businessesreportable segment | revenue | 2024-04-01 → 2025-03-31 | ¥37.0bn |
| Dispensing Pharmacy And Related Businessesreportable segment | revenue external | 2024-04-01 → 2025-03-31 | ¥37.0bn |
| Dispensing Pharmacy And Related Businessesreportable segment | segment assets | at 2025-03-31 | ¥16.5bn |
| Dispensing Pharmacy And Related Businessesreportable segment | segment profit | 2024-04-01 → 2025-03-31 | ¥596m |
| Ethical Pharmaceuticals Wholesaling Businessreportable segment | capex | 2024-04-01 → 2025-03-31 | ¥14.0bn |
| Ethical Pharmaceuticals Wholesaling Businessreportable segment | depreciation | 2024-04-01 → 2025-03-31 | ¥7.7bn |
| Ethical Pharmaceuticals Wholesaling Businessreportable segment | revenue | 2024-04-01 → 2025-03-31 | ¥2.64T |
| Ethical Pharmaceuticals Wholesaling Businessreportable segment | revenue external | 2024-04-01 → 2025-03-31 | ¥2.62T |
| Ethical Pharmaceuticals Wholesaling Businessreportable segment | revenue intersegment | 2024-04-01 → 2025-03-31 | ¥19.0bn |
| Ethical Pharmaceuticals Wholesaling Businessreportable segment | segment assets | at 2025-03-31 | ¥1.24T |
| Ethical Pharmaceuticals Wholesaling Businessreportable segment | segment profit | 2024-04-01 → 2025-03-31 | ¥33.1bn |
| Manufacturing Businessreportable segment | capex | 2024-04-01 → 2025-03-31 | ¥3.1bn |
| Manufacturing Businessreportable segment | depreciation | 2024-04-01 → 2025-03-31 | ¥3.5bn |
| Manufacturing Businessreportable segment | revenue | 2024-04-01 → 2025-03-31 | ¥54.1bn |
| Manufacturing Businessreportable segment | revenue external | 2024-04-01 → 2025-03-31 | ¥37.7bn |
| Manufacturing Businessreportable segment | revenue intersegment | 2024-04-01 → 2025-03-31 | ¥16.4bn |
| Manufacturing Businessreportable segment | segment assets | at 2025-03-31 | ¥73.0bn |
| Manufacturing Businessreportable segment | segment profit | 2024-04-01 → 2025-03-31 | ¥1.3bn |
| Self Medication Products Wholesaling Businessreportable segment | capex | 2024-04-01 → 2025-03-31 | ¥948m |
| Self Medication Products Wholesaling Businessreportable segment | depreciation | 2024-04-01 → 2025-03-31 | ¥346m |
| Self Medication Products Wholesaling Businessreportable segment | revenue | 2024-04-01 → 2025-03-31 | ¥265.7bn |
| Self Medication Products Wholesaling Businessreportable segment | revenue external | 2024-04-01 → 2025-03-31 | ¥265.3bn |
| Self Medication Products Wholesaling Businessreportable segment | revenue intersegment | 2024-04-01 → 2025-03-31 | ¥473m |
| Self Medication Products Wholesaling Businessreportable segment | segment assets | at 2025-03-31 | ¥93.0bn |
| Self Medication Products Wholesaling Businessreportable segment | segment profit | 2024-04-01 → 2025-03-31 | ¥3.0bn |
| Total Of Reportable Segments And Otherssegment total | capex | 2024-04-01 → 2025-03-31 | ¥18.8bn |
| Total Of Reportable Segments And Otherssegment total | depreciation | 2024-04-01 → 2025-03-31 | ¥11.9bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2024-04-01 → 2025-03-31 | ¥3.00T |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2024-04-01 → 2025-03-31 | ¥2.96T |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2024-04-01 → 2025-03-31 | ¥35.8bn |
| Total Of Reportable Segments And Otherssegment total | segment assets | at 2025-03-31 | ¥1.42T |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2024-04-01 → 2025-03-31 | ¥37.9bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 2,172
| Item | Context | Value | Unit |
|---|---|---|---|
| Dividend per share dividends of surplus | FilingDateInstant_Row2Member | 34.00 | |
| Number of male directors and other officers | FilingDateInstant | 9 | |
| Number of female directors and other officers | FilingDateInstant | 3 | |
| Ratio of female directors and other officers | FilingDateInstant | 0.250 | |
| Number of shares held ordinary shares information about directors and corporate auditors | FilingDateInstant_jpcrp030000-asr_E02962-000ArakawaRyujiMember | 71000 | |
| Number of shares held ordinary shares information about directors and corporate auditors | FilingDateInstant_jpcrp030000-asr_E02962-000FukujinYuusukeMember | 3012000 | |
| Number of shares held ordinary shares information about directors and corporate auditors | FilingDateInstant_jpcrp030000-asr_E02962-000OhasiSigekiMember | 8000 | |
| Number of shares held ordinary shares information about directors and corporate auditors | FilingDateInstant_jpcrp030000-asr_E02962-000TanakaTosikiMember | 5000 | |
| Number of shares held ordinary shares information about directors and corporate auditors | FilingDateInstant_jpcrp030000-asr_E02962-000ShimadaKoichiMember | 5000 | |
| Number of shares held ordinary shares information about directors and corporate auditors | FilingDateInstant_jpcrp030000-asr_E02962-000KinoshitaManabuMember | － | |
| Number of shares held ordinary shares information about directors and corporate auditors | FilingDateInstant_jpcrp030000-asr_E02962-000TakeuchiToshieMember | － | |
| Number of shares held ordinary shares information about directors and corporate auditors | FilingDateInstant_jpcrp030000-asr_E02962-000KunimasaKimikoMember | － | |
| Number of shares held ordinary shares information about directors and corporate auditors | FilingDateInstant_jpcrp030000-asr_E02962-000UedaYuujiMember | 14000 | |
| Number of shares held ordinary shares information about directors and corporate auditors | FilingDateInstant_jpcrp030000-asr_E02962-000ItoTakashiMember | － | |
| Number of shares held ordinary shares information about directors and corporate auditors | FilingDateInstant_jpcrp030000-asr_E02962-000KizakiHiroshiMember | － | |
| Number of shares held ordinary shares information about directors and corporate auditors | FilingDateInstant_jpcrp030000-asr_E02962-000IidukaSachikoMember | － | |
| Number of shares held ordinary shares information about directors and corporate auditors | FilingDateInstant | 3117000 | |
| Number of male directors and other officers proposal | FilingDateInstant | 9 | |
| Number of female directors and other officers proposal | FilingDateInstant | 3 | |
| Ratio of female directors and other officers proposal | FilingDateInstant | 0.250 | |
| Audit fees reporting company | Prior1YearDuration | 120000000 | JPY |
| Non audit fees reporting company | Prior1YearDuration | － | JPY |
| Audit fees reporting company | CurrentYearDuration | 118000000 | JPY |
| Non audit fees reporting company | CurrentYearDuration | － | JPY |
| Audit fees consolidated subsidiaries | Prior1YearDuration | 121000000 | JPY |
| Non audit fees consolidated subsidiaries | Prior1YearDuration | － | JPY |
| Audit fees consolidated subsidiaries | CurrentYearDuration | 129000000 | JPY |
| Non audit fees consolidated subsidiaries | CurrentYearDuration | － | JPY |
| Audit fees total | Prior1YearDuration | 242000000 | JPY |
| Non audit fees total | Prior1YearDuration | － | JPY |
| Audit fees total | CurrentYearDuration | 248000000 | JPY |
| Non audit fees total | CurrentYearDuration | － | JPY |
| Total amount of remuneration etc remuneration etc by category of directors and other officers | CurrentYearDuration_DirectorsExcludingAuditAndSupervisoryCommitteeMembersAndOutsideDirectorsMember | 190000000 | JPY |
| Base remuneration remuneration etc by category of directors and other officers | CurrentYearDuration_DirectorsExcludingAuditAndSupervisoryCommitteeMembersAndOutsideDirectorsMember | 147000000 | JPY |
| Bonus remuneration etc by category of directors and other officers | CurrentYearDuration_DirectorsExcludingAuditAndSupervisoryCommitteeMembersAndOutsideDirectorsMember | 37000000 | JPY |
| Share based compensation stock price linkage remuneration by category of directors and other officers | CurrentYearDuration_DirectorsExcludingAuditAndSupervisoryCommitteeMembersAndOutsideDirectorsMember | 6000000 | JPY |
| Number of directors and other officers remuneration etc by category of directors and other officers | CurrentYearDuration_DirectorsExcludingAuditAndSupervisoryCommitteeMembersAndOutsideDirectorsMember | 7 | |
| Total amount of remuneration etc remuneration etc by category of directors and other officers | CurrentYearDuration_DirectorsAppointedAsAuditAndSupervisoryCommitteeMembersExcludingOutsideDirectorsMember | 19000000 | JPY |
| Fixed remuneration remuneration by category of directors and other officers | CurrentYearDuration_DirectorsAppointedAsAuditAndSupervisoryCommitteeMembersExcludingOutsideDirectorsMember | 19000000 | JPY |
| Bonus remuneration etc by category of directors and other officers | CurrentYearDuration_DirectorsAppointedAsAuditAndSupervisoryCommitteeMembersExcludingOutsideDirectorsMember | － | JPY |
| Share based compensation stock price linkage remuneration by category of directors and other officers | CurrentYearDuration_DirectorsAppointedAsAuditAndSupervisoryCommitteeMembersExcludingOutsideDirectorsMember | － | JPY |
| Number of directors and other officers remuneration etc by category of directors and other officers | CurrentYearDuration_DirectorsAppointedAsAuditAndSupervisoryCommitteeMembersExcludingOutsideDirectorsMember | 1 | |
| Total amount of remuneration etc remuneration etc by category of directors and other officers | CurrentYearDuration_CorporateAuditorsExcludingOutsideCorporateAuditorsMember | 11000000 | JPY |
| Base remuneration remuneration etc by category of directors and other officers | CurrentYearDuration_CorporateAuditorsExcludingOutsideCorporateAuditorsMember | 11000000 | JPY |
| Bonus remuneration etc by category of directors and other officers | CurrentYearDuration_CorporateAuditorsExcludingOutsideCorporateAuditorsMember | － | JPY |
| Share based compensation stock price linkage remuneration by category of directors and other officers | CurrentYearDuration_CorporateAuditorsExcludingOutsideCorporateAuditorsMember | － | JPY |
| Number of directors and other officers remuneration etc by category of directors and other officers | CurrentYearDuration_CorporateAuditorsExcludingOutsideCorporateAuditorsMember | 2 | |
| Total amount of remuneration etc remuneration etc by category of directors and other officers | CurrentYearDuration_OutsideDirectorsAndOtherOfficersMember | 71000000 | JPY |
| Base remuneration remuneration etc by category of directors and other officers | CurrentYearDuration_OutsideDirectorsAndOtherOfficersMember | 71000000 | JPY |
| Bonus remuneration etc by category of directors and other officers | CurrentYearDuration_OutsideDirectorsAndOtherOfficersMember | － | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 24 of 24 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| balance sheet identity | pass |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |